Top

Journal of Cardiothoracic Surgery

Published in:

Open Access 01-12-2013 | Research article

Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma

Authors: Zhenfa Zhang, Anlei Wang, Bingsheng Sun, Zhongli Zhan, Kexin Chen, Changli Wang

Published in: Journal of Cardiothoracic Surgery | Issue 1/2013

Abstract

Background

Non-mucinous bronchioloalveolar carcinoma (BAC) is considered the early stage of lung adenocarcinoma and is classified as the lung adenocarcioma in situ (AIS) by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. This study was designed to investigate the gene expression differences between AIS (formerly non–mucinous BAC) and invasive lepidic predominant adenocarcinoma (LPA, formerly non-mucinous BAC pattern with >5 mm invasion, mixed type adenocarcinoma with BAC features) and to investigate the mechanism of the progression of lung adenocarcinoma in situ to invasive adenocarcinoma.

Methods

Gene expression analysis was performed by using Agilent 4 × 44 K Whole Human Genome Oligo Microarray on 10 fresh frozen tissue samples of AIS and LPA, respectively. Real time RT-PCR was used to validate the differential expression of 13 genes selected by cDNA microarray on fresh frozen tissue samples from 41 patients with lung adenocarcinoma and 4 genes were confirmed. These 4 genes were then validated by western blotting. Immunohistochemical staining for these validated genes was performed on formalin-fixed, paraffin-embedded tissue samples from 81 cases of lung adenocarcinomna.

Results

We identified a 13 gene expression signature by comparative analysis of gene expression. Expression of these genes strongly differed between AIS and LPA. Four genes (MMP-2, c-fos, claudin 1 (CLDN1) and claudin 10(CLDN10)) were correlated with the results of microarray and real time RT-PCR analyses for the gene-expression data in samples from 41 patients with lung adenocarcinoma. As confirmed by western blotting, the expression levels of MMP-2 and c-fos were higher in LPA than those in AIS; the expression levels of CLDN1 and CLDN10 in LPA were lower than those in AIS. Immunohistochemical staining for these genes in samples from 81 cases of lung adenocarcinoma demonstrated the expressions of CLDN1 and CLDN10 were correlated with overall survival of patients with lung adenocarcinoma.

Conclusions

CLDN1 and CLDN10 may play important roles in the development of AIS to LPA. Overexpression of CLDN1 and CLDN10 indicates a favorable prognosis for overall survival in some patients with lung adenocarcinoma. Expression of CLDN10 may be regulated by the c-fos pathway.

Available only for authorised users

Liebow AA: Bronchiolo-alveolar carcinoma. Adv Intern Med. 1960, 10: 329-358.PubMed

Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC: WHO Classification of Tumors: Pathology and Genetics of tumors of the Lung,Pleura, Thymus and Heart. 2004, Lyon: IARC Press, 35-44.

Travis WD, Brambilla E, Noguchi M: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society, International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011, 6: 244-285. 10.1097/JTO.0b013e318206a221.CrossRefPubMedPubMedCentral

Soh J, Toyooka S, Ichihara S, Asano H, Kobayashi N, Suehisa H, Otani H, Ymamoto H, Ichimura K, Kiura K, Gazdar AF, Date H: Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol. 2008, 3: 340-347. 10.1097/JTO.0b013e318168d20a.CrossRefPubMedPubMedCentral

Raz DJ, He B, Rosell R, Jablons DM: Bronchioloalveolar carcinoma: a review. Clin Lung Cancer. 2006, 7: 313-322. 10.3816/CLC.2006.n.012.CrossRefPubMed

Terasaki H, Niki T, Matsuno Y, Yamada T, Maeshima A, Asamura H, Hayabuchi N, Hirohashi S: Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003, 27: 937-51. 10.1097/00000478-200307000-00009.CrossRefPubMed

Sakuragi T, Sakao Y, Fujita H: Lymph node metastasis, recurrence, and prognosis in small peripheral lung adenocarcinoma: analysis based on replacement. Jpn J Thorac Cardiovasc Surg. 2002, 50: 424-9. 10.1007/BF02913176.CrossRefPubMed

Kondo D, Yamada K, Kitayama Y, Hoshi S: Peripheral lung adenocarcinomas: 10 mm or less in diameter. Ann Thorac Surg. 2003, 76: 350-5. 10.1016/S0003-4975(03)00340-0.CrossRefPubMed

Makimoto Y, Nabeshima K, Iwasaki H, Miyoshi T, Enatsu S, Shiraishi T, Iwasaki A, Shirakusa T, Kikuchi M: Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (<=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi’s type C tumours). Histopathology. 2005, 46: 677-84. 10.1111/j.1365-2559.2005.02126.x.CrossRefPubMed

10.

Jiang R, Jin Z, Liu Z, Sun L, Wang L, Li K: Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol Diagn Ther. 2011, 15: 347-352. 10.1007/BF03256470.CrossRefPubMed

11.

Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003, 19: 185-193. 10.1093/bioinformatics/19.2.185.CrossRefPubMed

12.

Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S, Chen WJ, Chen JJ, Yang PC: A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007, 356: 11-20. 10.1056/NEJMoa060096.CrossRefPubMed

13.

Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, Wheeler J, Gleave M, Sanghera J, Dedhar S: Regulationof tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell. 2004, 5: 79-90. 10.1016/S1535-6108(03)00281-2.CrossRefPubMed

14.

Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S: Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene. 2003, 22: 2021-2033. 10.1038/sj.onc.1206199.CrossRefPubMed

15.

Usami Y, Chiba H, Nakayama F: Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Hum Pathol. 2006, 37: 569-577. 10.1016/j.humpath.2005.12.018.CrossRefPubMed

16.

Sauer T, Pedersen MK, Ebeltoft K, Næss O: Reducedexpression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology. 2005, 16: 193-198. 10.1111/j.1365-2303.2005.00257.x.CrossRefPubMed

17.

Michl P, Barth C, Buchholz M, Lerch MM, Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Löhr M, Leder G, Iwamura T, Adler G, Gress TM: Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res. 2003, 63: 6265-6271.PubMed

18.

Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alò PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ: Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003, 9: 2567-2575.PubMed

19.

Soini Y: Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology. 2005, 46: 551-560. 10.1111/j.1365-2559.2005.02127.x.CrossRefPubMed

20.

Lee JW, Lee SJ, Seo J, Song SY, Ahn G, Park CS, Lee JH, Kim BG, Bae DS: Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia. Gynecol Oncol. 2005, 97: 53-59. 10.1016/j.ygyno.2004.11.058.CrossRefPubMed

21.

Agarwal R, D’Souza T, Morin PJ: Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005, 65: 7378-7385. 10.1158/0008-5472.CAN-05-1036.CrossRefPubMed

22.

Chao YC, Pan SH, Yang SC, Yu SL, Che TF, Lin CW, Tsai MS, Chang GC, Wu CH, Wu YY, Lee YC, Hong TM, Yang PC: Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med. 2009, 179: 123-133. 10.1164/rccm.200803-456OC.CrossRefPubMed

23.

Dhawan P, Singh AB, Deane NG: Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest. 2005, 115: 1765-1776. 10.1172/JCI24543.CrossRefPubMedPubMedCentral

24.

Escudero-Esparza A, Jiang WG, Martin TA: The Claudin family and its role in cancer and metastasis. Front Biosci. 2011, 16: 1069-1083. 10.2741/3736. Publisher: Tampa, Fla. United StatesCrossRef

25.

Jin T, George Fantus I, Sun J: Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of β-catenin. Cell Signal. 2008, 20: 1697-1704. 10.1016/j.cellsig.2008.04.014.CrossRefPubMed

26.

Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y, Furukawa Y: Involvement of claudin-1 in the β-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res. 2000, 12: 469-476.CrossRef

27.

Mankertz J, Hillenbrand B, Tavalali S, Huber O, Fromm M, Schulzke JD: Functional crosstalk between Wnt signaling and Cdx-related transcriptional activation in the regulation of the claudin-2 promoter activity. Biochem Biophys Res Commun. 2004, 314: 1001-1007. 10.1016/j.bbrc.2003.12.185.CrossRefPubMed

28.

Wagner EF, Eferl R: Fos/AP-1 proteins in bone and the immune system. Immunol Rev. 2005, 208: 126-140. 10.1111/j.0105-2896.2005.00332.x.CrossRefPubMed

29.

Preston GA, Lyon TT, Yin Y: Induction of apoptosis by c-Fos protein. Mol Cell Biol. 1996, 16: 211-218.CrossRefPubMedPubMedCentral

30.

Overall CM, Kleifeld O: Validating matrix metalloproteinases as drug targets and anti-cancer targets for cancer therapy. Nat Rev Cancer. 2006, 6: 227-238. 10.1038/nrc1821.CrossRefPubMed

31.

Duffy MJ, McGowan PM, Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol. 2008, 214: 283-293. 10.1002/path.2282.CrossRefPubMed

Title: Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma
Authors: Zhenfa Zhang
Anlei Wang
Bingsheng Sun
Zhongli Zhan
Kexin Chen
Changli Wang
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Cardiothoracic Surgery / Issue 1/2013
Electronic ISSN: 1749-8090
DOI: https://doi.org/10.1186/1749-8090-8-95

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Progressive cyanosis following Kawashima operation: slow resolution after redirection of hepatic veins

Mitral commissurotomy through the left ventricle apical orifice with Heart Ware left ventricular assist device implantation

Determination of mitral valve area with echocardiography, using intra-operative 3-dimensional versus intra- & post-operative pressure half-time technique in mitral valve repair surgery

Surgical techniques and results of the pulmonary artery reconstruction for patients with central non-small cell lung cancer

Early malperfusion, ischemia reperfusion injury, and respiratory failure in acute complicated type B aortic dissection after thoracic endovascular repair

Open heart surgery in Nigeria; a work in progress